Latest News & Features
Americas
American biotech 3Scan is combining robotics with machine learning and automation to offer microscopy services for the 3D analysis of cells, tissues, and organs. LSIPR met general counsel Nada Rastad to hear about some of the patenting challenges. 24 September 2018
Asia-Pacific
The Australian Competition & Consumer Commission announced yesterday that it has approved the merger of generic drugs companies Arrow and Apotex. 21 September 2018
Europe
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year. 20 September 2018
Americas
ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics. 20 September 2018
Americas
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report. 19 September 2018
article
Held in the US life sciences hub of Boston, LSX World Congress USA is bringing together investors and executive leaders from life sciences companies on October 10 and 11, as LSIPR finds out. 19 September 2018
Americas
Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments. 19 September 2018
Big Pharma
Researchers from three London universities and the Francis Crick Institute have joined together to form a hub for cancer biotherapeutics research and treatment, made possible by a £14 million investment from charity Cancer Research UK. 19 September 2018
Americas
The US Court of Appeals for the Federal Circuit yesterday overturned a Patent Trial and Appeal Board decision that had said chemical company DuPont hadn’t proved that a patent was invalid. 18 September 2018
Americas
Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million. 18 September 2018